Dr. Lagenaur is a molecular biologist with experience in virology and bacteriology and worked as a clinical microbiologist in both the human and veterinary fields. She received her doctorate in Microbiology and Immunology from Stanford University, and completed a post-doctoral fellowship at the University of California, San Francisco, on molecular characterization of viruses associated with HIV.
Dr. Lagenaur joined Osel Inc. in 1998. Osel is biotherapeutics company located in Mountain View, CA, whose lead product is LACTIN-V. LACTIN-V (Lactobacillus crispatus CTV-05) is a live biotherapeutic product under two INDs with the FDA to prevent recurrent urinary tract infection and bacterial vaginosis in women. LACTIN-V has just undergone a successful Phase 2b trail, showing that it reduced recurrence of BV following SOC treatment.
Dr. Lagenaur came to NIH in 2000 with her husband, and shortly thereafter joined Ed Berger’s lab (NIAID) as a guest under a CRADA to work on recombinant Lactobacilli expressing the HIV entry inhibitor CD4-17b. She later moved to Hamer/Berzofsky labs (NCI) under a CRADA to continue work on recombinant Lactobacilli expressing two different HIV inhibitors.
Dr. Lagenaur’s research interests are women’s health, the vaginal microbiome, lactobacilli, and HIV prevention in women.
